Renaissance Capital logo

Sema4 (CM Life Sciences) Priced, Nasdaq: SMFR

Blank check company formed by Casdin Capital and Corvex Management targeting a life science business (completed 7/22/2021).

Industry: SPAC

First Day Return: +2.5%

Industry: SPAC

We are a newly organized blank check company incorporated in July 2020 as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. While we may pursue an initial business combination target in any industry, sector or geographic region, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. Our team intends to leverage the strong life sciences knowledge base and public and private market experience of our sponsor with the goal of executing a successful business combination in the life sciences sector. Our sponsor is an affiliate of Eli Casdin, founder and Chief Investment Officer of Casdin Capital, and of Keith Meister, founder and Chief Investment Officer of Corvex Management, two leading investment firms. CM Life Sciences was founded to take advantage of a dynamic life sciences sector that continues to be buoyed by innovation. With a broadening set of applications for biotechnology that includes research tools and infrastructure, diagnostics, therapeutics, data, and industrial outputs, the life sciences sector offers compelling opportunities for investors who possess a broad overview and understand the trends and themes.
more less

Sema4 (CM Life Sciences) (SMFR) Performance